leisure time -WSS

leisure time

author：explore 2025-10-02 22:58:04 - browse：13

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Beam Therapeutics to lay off 20% of its staff, re

WSS

What to know about 'Guardians of the Galaxy Vol. 3' as it hits Disney+

Jesse Tyler Ferguson makes friendship bracelets for Taylor Swift's Eras Tour

Parkland mass shooting to be reenacted for lawsuit

CEOs share strategies for surviving biotech slump

Judge in Trump's Jan. 6 case gives attorneys 2 weeks to propose trial date

Judge in Trump's Jan. 6 case gives attorneys 2 weeks to propose trial date

entertainment

leisure time

focus

How to save PrEP access — and even expand it

Pope greeted like rockstar, appears revitalized at 'Catholic Woodstock' in Portugal

Novavax promises a turnaround & Lilly roils the obesity market

First Opinion Podcast: Long Covid needs a new approach

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Climate activists disrupt London Pride march to protest corporate sponsorship

Malaria cases in Florida and Texas: Here’s what you need to know

NIH confirmation hearing shows politicization of research

As demand for Covid shots wanes, Moderna seeks its next success

STAT Summit: How a Chicago ER doctor tackles gun violence

focus

FDA gives detailed accounting of AI

US Marines prepare to be put on commercial ships to deter Iranian harassment in Strait of Hormuz

Prosecutors seek bail revocation for FTX founder Sam Bankman

Rock icon Freddie Mercury pre

2023 STAT Wunderkinds: get to know the winners

Does Medicare's free annual wellness visit do any good?

leisure time

explore

leisure time

hotspot